H01Q 3/24 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the orientation by switching energy from one active radiating element to another, e.g. for beam switching
H01Q 1/27 - Adaptation for use in or on movable bodies
H02J 50/00 - Circuit arrangements or systems for wireless supply or distribution of electric power
H02J 50/27 - Circuit arrangements or systems for wireless supply or distribution of electric power using microwaves or radio frequency waves characterised by the type of receiving antennas, e.g. rectennas
2.
SURFACTANT-LOADED MOF-BASED ANTIVIRAL FABRIC FOR USE IN FACEMASKS AND RESPIRATORS
A method for developing an antimicrobial includes coating a cyclodextrin-based metal-organic framework (CD-MOF-1) solution on a polypropylene fabric. The method further includes forming a MOF-coated fabric based on the CD-MOF-1 coating. The method further may load a benzalkonium chloride (BAC)-based surfactant on the MOF-coated fabric to develop the antimicrobial fabric.
D06M 13/50 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compoundsSuch treatment combined with mechanical treatment with organometallic compoundsTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compoundsSuch treatment combined with mechanical treatment with organic compounds containing boron, silicon, selenium or tellurium atoms
D06M 15/03 - Polysaccharides or derivatives thereof
D06M 101/20 - Polyalkenes, polymers or copolymers of compounds with alkenyl groups bonded to aromatic groups
3.
Synthesis Of Mxene Suspensions With Improved Stability
Provided are enhanced MXene materials made from MAX-phase precursors that comprise an excess of metal A. The resultant enhanced MXenes exhibit improved stability over periods of days and months, particularly when stored in aqueous media.
C01B 32/907 - OxycarbidesSulfocarbidesMixture of carbides
H01B 1/04 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of carbon-silicon compounds, carbon, or silicon
4.
COMPOSITIONS AND METHODS COMPRISING MICROPARTICLE-TRANSFERRING MACROPHAGES
The present disclosure generally relates to compositions and methods comprising conditioned macrophages. The present disclosure further generally relates to methods of treating diseases and conditions comprising the use of conditioned macrophages, such as for the treatment of fibrosis. In some aspects, the methods described herein comprise the use of conditioned macrophages for treating pulmonary fibrosis.
A shunt prosthesis comprises a synthetic tube having an inner wall defining a fixed inner diameter of the synthetic tube and a layer of hydrogel of a predetermined thickness coating the inner wall of the synthetic tube such that the layer of hydrogel has a fixed outer diameter and such that an inner diameter of the layer of hydrogel defines a diameter of a lumen extending through and defined by the shunt prosthesis. The layer of hydrogel being configured such that the predetermined thickness of the layer of hydrogel is reducable in vivo over a predetmined period of time by controlling the crosslinking density of the layer of hydrogel. A method of controlling flow through a shunt prosthesis is also provided.
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
Processes of photocatalytically generating molecular hydrogen (H2) and systems for carrying out the processes. Liquid water is contacted with an amount of a ID and/or 2D carbon-doped nanofilament-based photocatalyst material composition and a hole scavenger chemical, optionally under an inert gas purge, at temperature of 100° C. or less, generating gaseous molecular hydrogen by irradiating the liquid water, the hole scavenger chemical, and the photocatalyst for about 1 to 300 hours with at least one sun illumination (UV-Vis light (250-650 nm)).
Provided are methods of stabilizing MXene compositions using polyanionic salts so as to reduce the oxidation of the MXenes. Also provided are stabilized MXene compositions.
An article, a method of making the same, and a method of using the same are provided. Such an article includes at least one coated layer, which includes a substrate and a coating disposed on the substrate. The coating includes a layered nanomaterial and a solute embedded and distributed in the layered nanomaterial. The solute comprises at least one salt soluble in a solvent. The substrate comprises a polymer, for example, a high-performance polymer such as polyether ether ketone and poly(para-phenylene terephthalamide). The article is used for thermal management applications, for example, as protective garment.
B05D 1/18 - Processes for applying liquids or other fluent materials performed by dipping
B05D 5/12 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain a coating with specific electrical properties
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
H05B 3/14 - Heating elements characterised by the composition or nature of the materials or by the arrangement of the conductor characterised by the composition or nature of the conductive material the material being non-metallic
H05B 3/16 - Heating elements characterised by the composition or nature of the materials or by the arrangement of the conductor the conductor being mounted on an insulating base
9.
METHODS AND COMPOSITIONS FOR OPTOGENETICALLY ENGINEERED CELLS FOR NEURAL REPAIR
Compositions and methods for administering optogenetically-activatable cells for repair of the nervous system after injury or disease are contemplated herein.
A composite that includes a layered MXene comprising at least two layers, and an amount of a chalcogen confined between the at least two layers. An electrode that includes a composite that includes a layered MXene comprising at least two layers, and an amount of a chalcogen confined between the at least two layers. Power cells that include the composite. A method, comprising: with an intercalant spacer, effecting an increase in an interlayer spacing in a multilayered MXene composition; and effecting intercalation of a chalcogen into the interlayer spacing so as to confine the chalcogen between layers of the multilayered MXene composition, and optionally effecting removal of the intercalant spacer.
A method, comprising: contacting a multilayered MXene comprising at least one of halogen or chalcogen terminations with cations dissolved in a non-aqueous solvent so as to give rise to a cation-intercalated MXene; and delaminating the cation-intercalated MXene. A MXene layer, the MXene layer comprising uniform or essentially uniform terminations. A method, comprising: delaminating a cation-intercalated MXene comprising at least one of halogen or chalcogen terminations so as to give rise to a MXene layer comprising uniform or essentially uniform terminations.
Cancers develop specific metabolic adaptations such as the opportunistic utilization of acetate as an alternative carbon source and the generation of acetyl-CoA mediated by ACSS-2, which is upregulated in response to nutrient and hypoxic stress. This pathway can fuel various processes involving acetyl-CoA, including de novo fatty acid synthesis and protein acetylation. Provided herein are methods of treating a cancerous disease in a subject using compounds that inhibit ACSS-2.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/04 - Antineoplastic agents specific for metastasis
13.
BRAIDED MULTI-ELECTRODE EMG NEEDLES FOR ADVANCED ELECTRODIAGNOSTICS
A braided needle is provided herein. The braided needle includes base needle configured for electromyography. The braided needle also includes a plurality of wires braided around an exterior surface of the base needle and along a length of the base needle, the plurality of wires being configured to transmit multiple electrical signals in connection with a biological material, the plurality of wires being further configured for electromyography.
The present invention provides a method of treating or ameliorating cocaine use disorder in a subject in need thereof, comprising administering to the subject a compound useful within the disclosure.
C22C 1/04 - Making non-ferrous alloys by powder metallurgy
C22C 32/00 - Non-ferrous alloys containing at least 5% by weight but less than 50% by weight of oxides, carbides, borides, nitrides, silicides or other metal compounds, e.g. oxynitrides, sulfides, whether added as such or formed in situ
C22F 1/14 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of noble metals or alloys based thereon
16.
QUANTIFICATION OF ON-TARGET AND OFF-TARGET GENE EDITING ACTIVITY
Described herein are methods useful for quantification of on-target and off-target gene editing activity. The method comprises establishing a first consensus labeling in a genomic DNA in a first plurality of cells, which comprises introducing a first tag at a first plurality of pre-determined locations in the genomic DNA; performing the genomic editing assay with a nucleotide comprising a second tag; identifying locations of genome editing activities by detecting signals of the second tag in reference to signals of the first tag in the first consensus labeling; and calculating genome editing efficiencies at an on-target location or an off-target location.
A one-dimensional lepidocrocite titanium oxide material, the material having a surface functionality covalently bound thereto. Also provided is a method of functionalizing a one-dimensional lepidocrocite titanium oxide material (1DL), comprising: contacting the 1DL material with a hydrocarbon halide or a hydrocarbon alcohol under such conditions that the hydrocarbon halide or hydrocarbon alcohol reacts with the 1DL material so as to give rise to a reaction product, the reaction product being covalently bound to the 1DL material.
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
Provided are methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects among higher and lower risk categories for having hepatocellular carcinoma, and methods of treating and managing treatment of subjects that are suspected or at risk of having hepatocellular carcinoma. Although previous work has attempted to address the need for a highly sensitive, early predictor of hepatocellular carcinoma by assessment of one or more biological factors, none have approached the degree of sensitivity that is required for clinically relevant determination of whether a subject, especially a non-symptomatic subject, has that condition. The present inventors have discovered that certain combinations of factors fulfill this need by conferring a high level of accuracy that was not previously attainable.
This disclosure is directed to composites comprising a polymeric film coated on one or both sides with a MXene material, as well as lithium metal electrodes and components thereof, including MXene-polymer composite separators.
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
D02G 3/44 - Yarns or threads characterised by the purpose for which they are designed
D06M 11/58 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
G01L 19/00 - Details of, or accessories for, apparatus for measuring steady or quasi-steady pressure of a fluent medium insofar as such details or accessories are not special to particular types of pressure gauges
An electrode, comprising: a portion of MXene, the portion of MXene optionally being free of materials other than the MXene; and (a) a sealing material, the sealing material at least partially enclosing the portion of MXene, and the sealing material defining an opening through which a sensing region of the portion of MXene is exposed; or (b) a substrate, the portion of MXene being disposed on the substrate. An electrode, comprising: a fiber; a first coating superposed on the fiber, the first coating having a thickness and comprising a MXene composition, the MXene composition optionally comprising aligned MXene flakes, the first coating optionally having a uniform thickness along the length of the fiber; and a second coating superposed on the fiber.
A method, comprising: forming a porous MAX-phase material. A MAX-phase material, the MAX-phase material made according to the present disclosure. A MXene material, the MXene material formed by removal of the A-group element of a MAX-phase material made according to the present disclosure.
An energy storage cell, comprising: a layer comprising a plurality of fibers, the plurality of fibers having a MXene material disposed thereon; an electrolyte disposed on the layer; a first conductor in electronic communication with the electrolyte; and a second conductor in electronic communication with the electrolyte. Energy storage devices, the energy storage device comprising at least one energy storage cell according to the present disclosure. A method, comprising the use of an energy storage device according to the present disclosure.
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
H01M 50/211 - Racks, modules or packs for multiple batteries or multiple cells characterised by their shape adapted for pouch cells
H01M 50/247 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders specially adapted for portable devices, e.g. mobile phones, computers, hand tools or pacemakers
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
24.
TWO-DIMENSIONAL (2-D) ARRAYS OF TRANSITION METAL NITRIDES FOR LI-METAL ANODES
The present disclosure is directed to freestanding films for a lithium-metal-anode comprising a 2D arrays of nanocrystals of a transition metal nitride, carbide, or mixture and optionally a MXene as a conductive binder, and methods of making and using the same.
B60R 9/06 - Supplementary fittings on vehicle exterior for carrying loads, e.g. luggage, sports gear or the like at vehicle front or rear
B60R 11/00 - Arrangements for holding or mounting articles, not otherwise provided for
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
25.
NANOMATERIAL-BASED PROCESSING OF DYES AND ORGANIC COMPOUNDS
Provided is a method, comprising contacting a composition that comprises metal oxide nanofilaments to a dye and/or an organic compound under such conditions that the dye and/or the organic compound undergoes at least partial decomposition or degradation, the metal oxide nanofilaments the metal oxide nanofilaments optionally comprising titanium, the metal oxide nanofilaments optionally comprising carbon, the structure of the oxide nanofilaments optionally being an lepidocrocite structure; and further optionally comprising illuminating the composition and the dye and/or the organic compound. Also provided is a system, the system comprising a conduit and an amount of a composition that comprises a metal oxide nanofilaments, the conduit placing the composition into fluid communication with a process stream, the process stream comprising a dye and/or an organic compound.
A62D 3/17 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by subjecting to electric or wave energy or particle or ionizing radiation to electromagnetic radiation, e.g. emitted by a laser
Provided is a method, comprising: providing a solution of delaminated MXene material and a first ionic intercalant; and contacting the solution with a second ionic intercalant so as to exchange the first ionic intercalant and the second ionic intercalant so as to give rise to flocculated portions of the MXene material and a supernatant that comprises the first ionic intercalant and the second ionic intercalant. Also provided is a MXene dispersion, comprising a plurality of portions of single-layer and/or few-layer MXene dispersed in a solvent, the solvent comprising a first ionic intercalant and a second ionic intercalant. Also provided is a stable MXene dispersion, comprising a plurality of portions of single-layer and/or few-layer MXene dispersed in a solvent, the solvent comprising an ionic intercalant, the ionic intercalant optionally being present in supersaturated form.
The application relates to the healing of wounds. Provided herein are methods directed to treatment of hard-to-heal or chronic wounds by sequential administration of M1 and M2 macrophages to the wound site
The application relates to the delivery of immunomodulatory molecules, including cytokines, to the situs of tissue scaffolds, and wounds including injuries.
A method, comprising: contacting a composition comprising metal oxide-based nanofilaments to an initial sample that comprises a metal ion and/or a metal under such conditions that at least some of the metal ion and/or the metal associates with the metal oxide nanofilaments, the metal oxide nanofilaments having a lepidocrocite structure and the metal oxide nanofilaments optionally comprising titanium, and optionally comprising illuminating the composition and metal oxide nanofilaments and/or metal.
Described herein are reagents, methods, and kits for identifying organisms across multiple taxonomic domains in a sample. The method includes performing a multiplex polymerase chain reaction (PCR) with the sample using a plurality of primer pairs that are capable of amplifying at least one identifying nucleic acid of organisms across multiple taxonomic domains, thereby generating amplicons of organisms present in the sample. The method further includes performing sequencing on the amplicons to obtain sequencing reads of the amplicons. The method further includes identifying organisms in the sample based on the sequencing reads. Also described herein are kits for perfoming the methods contemplated herein.
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
An electrolyte for a sulfur battery including a compound of Formula (I), and mesomers thereof, wherein R1 and R2 are selected from hydrogen, and the following optionally substituted groups: C1-C20 hydrocarbyl groups, C4-C20 aryl group, C4-C20 heterocyclic groups, C2-C20 alkenyl groups, C1-C20 alkoxy groups, —NR3R4, —SH, and-OR5; and R3-R5 are selected from hydrogen, and the following optionally substituted groups: C1-C20 hydrocarbyl groups, C4-C20 aryl groups, C4-C20 heterocyclic groups, C2-C20 alkenyl groups, and C1-C20 alkoxy groups, the optional substitutions may be independently selected from a C1-C5 alkyl group, a C4-C10 aryl group, —NH2, —SH, —OH, a C2-C4 alkenyl group, and a group according to Formula (A), wherein R is the same as any one of R3 R5; a non-aqueous organic solvent, and a salt.
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/0567 - Liquid materials characterised by the additives
The present disclosure relates, in part, to compounds, compositions, and methods for treatment, ameliorating, and/or prevention of certain neurodegenerative diseases and/or cancers.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
33.
Coating Approach to Prevent Agglomeration of Spherical Lightweight Aggregate (LWA) During Sintering
During lightweight aggregate (LWA) production through sintering process, formation of liquid phase captures emitted gas to form pores in the LWA and leads to successful bloating. As the LWA undergoes sintering in the kiln, the liquid phase starts to form on the LWA surface. Accordingly, in a rotary kiln where the LWA are continually rolling over each other, the touching surfaces of LWAs with liquid phase start to adhere together and form lumps of LWA exiting the furnace. This method prevents agglomeration of spherical LWA during sintering. The LWA can be produced from clay, slate, shale, and potentially other waste materials. This method results in production of discrete spherical LWA particles that can be coated with waste fly ash particles to form a thin layer on the surface of LWA that will not melt during sintering and will prevent touching surfaces of LWA particles from sticking together and forming lumps.
Described herein are compounds useful as glutamate transport modulators, such as GLT-1 modulators. Also described herein is a method of increasing glutamate clearance by a GLT-1 containing cell, the method including contacting the cell with a compound contemplated herein. Also described herein is a method of preventing, treating and/or ameliorating a neurological disorder in a subject in need thereof, the method including administering to the subject an effective amount of a compound contemplated herein.
C07D 295/12 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 295/16 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
35.
NANOMATERIAL-BASED ADSORPTION PROCESSING AND CATALYSIS
A method, comprising: to an initial sample that has an initial concentration of urea in solution, contacting a composition comprising metal oxide nanofilaments under such conditions that at least some of the urea adsorbs to the metal oxide nanofilaments so as to give rise to a final concentration of urea in the solution A device for removing urea from an initial aqueous solution of urea, the device comprising an exchangeable cartridge of metal oxide nanofilaments composition through which the initial aqueous solution is directed to pass, the passage adapted to allow the initial aqueous urea solution to contact the metal oxide nanofilaments contained in the cartridge. Contacting a composition comprising metal oxide-based nanofilaments to an initial sample that comprises a metal ion and/or a metal under such conditions that at least some of the metal ion and/or the metal associates with the metal oxide nanofilaments.
B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
36.
INORGANIC GELS WITH 1-DIMENSIONAL LEPIDOCROCITE PHASE TITANIA-BASED NANOFILAMENTS
A gel composition, comprising; a plurality of one-dimensional lepidocrocite (1DL) titanate filaments associated with one another so as to form a gel. A method, comprising: contacting an organic acid to a suspension of 1DL titanate filaments, the contacting being performed under conditions such that the 1DL titanate filaments become associated with one another so as to form a gel.
The present invention relates to the discovery of compositions and methods for altering Amyloid Precursor Protein (APP) processing. Alerting APP processing is aids the treatment of neuropathological disorders such as those associated with HIV infection and Alzheimer's disease (AD). The invention includes fusion protein constructs that include an effector protein and an HSV US9 protein or functionally active fragment thereof that reduce the amount of amyloid □-protein produced in a cell.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
38.
METHOD FOR GENERATION OF NOVEL MATERIALS USING NANOSECOND-PULSED DISCHARGE PLASMA IN LIQUID PHASE
The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
MXene-coated antennas, and associated devices and methods of manufacture, are described herein. In one aspect, an antenna may include an antenna body, where the antenna body has a coated region with a MXene film conformally coated thereon. The implementation of MXene-based waveguide components provides an example of a facile, convenient realization of 3D-printed polymer devices with performance levels as high as metallic waveguides. The waveguide and other conductive components can be additively manufactured using commonly available 3D printers and commercially available polymers. Dip-coating of MXene provides a general solution for realizing geometrically complex metal-like 3D structures. The disclosure provides herein the implementation of thru, bent, twisted, and discontinuous filtering waveguides, each of which can be utilized to manipulate the propagation of electromagnetic waves.
The present invention provides novel methods for immobilizing and/or optically mapping oligonucleotides, the method comprising immobilizing the oligonucleotides on a micropatterned substrate. In another aspect, the invention provides a method for mapping a genome, wherein the method is capable of resolving a single nucleotide polymorphism (SNP), the method comprising introducing to the genome a CRISPR/Cas9 system comprising at least one single-guide RNA (sgRNA) specific for a target sequence or a plurality of target sequences across the genome and a Cas9 D10A, wherein the CRISPR/Cas9 system nick labels the target sequence, and the target sequence or genome is analyzed.
The present invention(s) is directed to novel conductive Mn+1Xn(Ts) compositions exhibiting high volumetric capacitances, and methods of making the same. The present invention(s) is also directed to novel conductive Mn+1Xn(Ts) compositions, methods of preparing transparent conductors using these materials, and products derived from these methods.
C04B 35/56 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides
C04B 35/58 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides
The present disclosure is directed to nanocomposites comprising a co-sintered composition of a MXene crystal form composition and an inorganic oxide, or oxide-type ceramic and methods of making and using the same.
C04B 35/56 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides
C04B 35/453 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zinc, tin or bismuth oxides or solid solutions thereof with other oxides, e.g. zincates, stannates or bismuthates
The invention relates to the compositions and methods for complete excision of HIV-1 proviral genomes including viral quasi-species (vQS) from an HIV-1-infected human. The invention includes a composition of guide RNAs (gRNAs) designed to specifically target the HIV-1 LTR region or any other region of the HIV-1 genome. The invention further includes a method for treating an HIV-1-infected human using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system and the compositions of the present invention.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
D02G 3/44 - Yarns or threads characterised by the purpose for which they are designed
D06M 11/58 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
G01L 19/00 - Details of, or accessories for, apparatus for measuring steady or quasi-steady pressure of a fluent medium insofar as such details or accessories are not special to particular types of pressure gauges
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
Inventor
Inman, Corey Alexander
Capobianco, Jr., Joseph A.
Gogotsi, Yury
Abstract
Herein we demonstrate a method of high energy delamination called high pressure homogenization (HPH) that combines high shear, cavitation forces, and impact forces to delaminate MXene without any post-process refinement steps or chemical intercalants. HPH-delaminated MXene can be made at scale with high throughput and yield with virtually no waste. We demonstrate the viability of this process by fabricating free-standing films with the material for use as electrodes for energy storage, and as an effective antimicrobial coating with a two-log reduction in pathogenic microbes.
Disclosed is a method for treating actinic keratosis of tissue of a patient, the method including contacting non-thermal, atmospheric pressure plasma over areas of the tissue having actinic keratosis for a time and at treatment conditions effective to give rise to an at least partial amelioration of the keratosis.
Described herein is a method of categorizing a cancer (such as into TEL+ cancer or ALT+ cancer). The method includes performing a global analysis of telomere lengths in cancer cells of the cancer, and determining the category of the cancer based on patterns of telomere lengths. Also described herein is a method of treating cancer based on the categorizing of the cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
abb wherein M is at least one element selected from the group consisting of Groups 3, 4, 5, 6, or 7, Q is at least one element (here, O is excluded) selected from the group consisting of Groups 12, 13, 14, 15, or 16, a is 0 or more and 2 or less, and b is more than 0 and 2 or less, wherein in a Raman spectrum, an average intensity at 745 to 765 cm-1is smaller than an average intensity at 735 to 745 cm-1, and wherein a pore volume is 0.060 cc/g or more.
A nondestructive evaluation method for determining the material used in a below-ground service line includes inserting a probe with a wave measurement device therein into an area corresponding to a location of a service line; generating a service line wave through an exposed portion of the service line using a vibratory shaker or other mechanical excitation; measuring, by the wave measurement device, a substrate wave created by the service line wave passing thought the service line and into the substrate; identifying, by a data acquisition system, the service line wave velocity and attenuation; comparing the service line wave velocity and attenuation to a known set of wave velocities and attenuations in service lines according to a service line material; and identifying the service line material in the service line by comparing the wave velocity and attenuation in the service line with the known set of wave velocities and attenuations.
The disclosure provides compounds of formula (II) having the structure:
The disclosure provides compounds of formula (II) having the structure:
The disclosure provides compounds of formula (II) having the structure:
Compounds of formula (II) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
53.
COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION
One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.
A wireless charging station installed on the seafloor is equipped with multiple wireless transmitter coils and powered by a large-capacity lithium-battery-based energy storage system (ESS). Correspondingly, small-size wireless receiver coils are installed inside underwater robots and vehicles. When the battery is low in the underwater devices, the robots and vehicles automatically swim to the charging station and land in a specific charging region. After identifying the robots and vehicles, the wireless charging station can automatically start a wireless charging operation.
H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
B60L 53/126 - Methods for pairing a vehicle and a charging station, e.g. establishing a one-to-one relation between a wireless power transmitter and a wireless power receiver
55.
TUNEABLE MXENE-BASED LENS DESIGN FOR SPECIFIC WAVELENGTH FILTRATION TO AID OCULAR DISORDERS AND PROTECT FROM POTENTIAL HARMFUL RADIATION
Provided are ophthalmic components (e.g., eyeglass lenses and contact lenses) that include a two dimensional crystalline solid material dispersed in a matrix material. The disclosed components can selectively filter light of selected wavelengths, thereby making the components suitable for use by individuals who may suffer from color vision deficiency conditions. The two dimensional crystalline solid material comprises at least one layer comprising a substantially two-dimensional array of crystal cells; each crystal cell having an empirical formula of M(n+1)X(n), such that each X is positioned within an array of M, wherein M is at least one Group IIIB, IVB, VB, VIB or VIIB metal, and wherein X is C and/or N.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
An antimicrobial amphiphilic copolymer comprising units derived from one or more hydrophobic polymers and one or more hydrophilic polymers, wherein the copolymer is selected from the group consisting of non-ionic and anionic copolymers and the copolymer is a random copolymer or a block copolymer, methods for making the copolymer, coatings made from the copolymer and medical devices coated with the copolymer.
C08F 299/02 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates
ab b wherein M is at least one element selected from the group consisting of Groups 3, 4, 5, 6, or 7, Q is at least one element (here, O is excluded) selected from the group consisting of Groups 12, 13, 14, 15, or 16, a is 0 or more and 2 or less, and b is more than 0 and 2 or less.
B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
58.
Directable Tunnel Device for Subcutaneous Implantable Cardio Defibrillator
A directional tunnel device for a subcutaneous implantable device is provided. The tunnel device includes an elongate outer sleeve having an open proximal end and an open distal end. An elongate outer trough has a trough proximal end, a trough distal end, and a concave cradle extending between the trough proximal end and the trough distal end. The outer trough is sized to slidingly fit inside outer sleeve such that the outer sleeve is slidable externally along the outer trough. An inner glide rests in the cradle. The inner glide includes an inner trough, a guide arm connected to a distal end of the inner trough, and a pivot arm connected to a distal end of the guide arm.
An electrolyte solvent having a dielectric constant of 10 or less comprising: a) 0% to 30% by volume of one or more of components i)-iii), based on a total volume of the electrolyte solvent: i) one or more unsubstituted cyclic carbonate(s): ii) one or more unsubstituted lactone(s); and iii) one or more unsubstituted oxazolidine(s); and b) 70% to 100% by volume of one or more of components iv)-vii), based on the total volume of the electrolyte solvent: iv) one or more substituted cyclic carbonate(s) having 3-15 carbon atoms: v) one or more substituted lactone(s) having 3-15 carbon atoms; and vi) one or more substituted oxazolidine(s) having 3-15 carbon atoms; and vii) one or more acyclic carbonate(s) having 2-20 carbon atoms. A method of making a cathode and cathodes and batteries made by the methods are also disclosed.
The present disclosure relates, in one aspect, to hydrogel compositions comprising a nanoparticle, functionalized polymer, and a therapeutic agent. In certain embodiments, the hydrogel compositions of the disclosure are suitable for local delivery of a therapeutic agent.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Korea Institute of Science and Technology (Republic of Korea)
Inventor
Gogotsi, Yury
Anasori, Babak
Alhabeb, Mohamed H.
Hatter, Christine B.
Koo, Chong Min
Hong, Soon Man
Shahzad, Faisal
Abstract
The present disclosure is directed to materials which provide electromagnetic shielding and methods of providing such electromagnetic shielding. In particular, the present disclosure describes the use of two-dimensional transition metal carbide, nitride, and carbonitride materials for this purpose.
Reconfigurable intelligent surfaces (RISs) are an emerging transmission technology to aid wireless communication. However, the potential of using RIS to mitigate directed energy weapons (DEW) is not widely recognized. Described herein are RIS (based on spiral antenna elements) to aid the mitigation of high-energy radio-frequency (RF) sources applied to a DEW. For example, integrating a broadband circularly-polarized antenna system with RIS technology can successfully mitigate DEW attacks across a wide range of frequencies regardless of how radio waves are polarized. A spiral antenna is simulated that operates between 1.3 GHz and 7 GHz with a 3-dB axial ratio bandwidth (ARBW) covering 2 GHz-7 GHz. Full-wave simulation results show the potential promising application of RIS for the mitigation of DEW attacks.
H01Q 5/25 - Ultra-wideband [UWB] systems, e.g. multiple resonance systemsPulse systems
H04B 7/04 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas
63.
FAULT CURRENT BYPASS BASED SOLID STATE CIRCUIT BREAKERS AND ACTIVE CLAMPING SNUBBERS FOR DC CIRCUIT BREAKERS
Solid-state circuit breakers (SSCBs) have been witnessing an impressive progress with the aid of wide bandgap (WBG) devices such as silicon carbide (SiC) MOSFETs. Along with obtaining high efficiency as the result of low on-state resistance, response times have been gaining remarkable achievements in microseconds range. Not only that, the reported successes in control and gate drivers design and incorporating fault detection/location techniques in SSCBs are promising. A MOV-resistive capacitive switch (MOV-RCS) snubber for solid state circuit breakers addresses the following: 1) the MOV degradation issue in DCCBs is solved, 2) the maximum allowable DC bus voltage on DCCBs is extended. The solid state circuit breaker and an active clamping snubber includes a first circuit including a fault current bypass based solid state breaker for low voltage direct current systems.
H03K 17/0812 - Modifications for protecting switching circuit against overcurrent or overvoltage without feedback from the output circuit to the control circuit by measures taken in the control circuit
H02H 3/087 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to excess current for DC applications
64.
METHODS AND COMPOSITIONS FOR DREADD-ACTIVATABLE CELLS FOR NEURAL REPAIR
Provided herein are methods of training a machine-learning model to detect a neurological condition. The methods include providing a neurological condition dataset comprising neurological condition text embeddings, the neurological condition text embeddings including large language model (LLM) text embeddings from subjects having the neurological condition; providing a control dataset comprising control text embeddings, the control text embeddings including LLM text embeddings from healthy subjects; and training the machine-learning model using the neurological condition dataset and the control dataset, forming a trained machine-learning model configured to detect a neurological condition. Also provided herein are methods of detecting a neurological condition using the trained machine-learning model.
Disclosed herein are thin films and methods of forming thin films. An example thin film may comprise Ba—Ti—O configured to exhibit a structure where a distance of one or more neighboring Ti—Ti atoms is less than 3 Å.
H01G 7/06 - Capacitors in which the capacitance is varied by non-mechanical meansProcesses of their manufacture having a dielectric selected for the variation of its permitivity with applied voltage, i.e. ferroelectric capacitors
68.
ARTIFICIAL INTELLIGENCE ASSISTED COMPUTATIONAL FRAGMENT-BASED DRUG DESIGN
Provided herein are methods for improving drug discovery using artificial intelligence to identify compounds that are expected to have potent binding affinities at therapeutic targets of interest.
G06F 30/20 - Design optimisation, verification or simulation
G06F 18/2113 - Selection of the most significant subset of features by ranking or filtering the set of features, e.g. using a measure of variance or of feature cross-correlation
G06F 18/2115 - Selection of the most significant subset of features by evaluating different subsets according to an optimisation criterion, e.g. class separability, forward selection or backward elimination
G06F 18/2132 - Feature extraction, e.g. by transforming the feature spaceSummarisationMappings, e.g. subspace methods based on discrimination criteria, e.g. discriminant analysis
A material, comprising: a coherent structure comprising a plurality of entangled titania filaments having a lepidocrocite crystal structure. A method, comprising: with a suspension comprising (1) a plurality of titania filaments having a lepidocrocite crystal structure and (2) a solvent, effecting at least partial removal of the solvent so as to give rise to a material according to the present disclosure. A composition, comprising: a plurality of titania filaments having a lepidocrocite crystal structure; and a solvent, the plurality of titania filaments being suspended in the solvent.
Processes of producing nanoparticles from solid phase precursor non-nanoparticles. Contacting a solid phase precursor non-nanoparticle selected from oxides of metals and metalloids, carbides of metals and metalloids, nitrides of metals and metalloids, borides of metals and metalloids, silicides of metals and metalloids, and phosphides of metals and metalloids, and mixtures thereof, with one or more onium ions in water in a vessel. Some processes can be one pot processes. The vessel is agitated and held at temperature for a time sufficient to form nanoparticles with the same crystalline structure as the solid phase precursor non-nanoparticle as determined by XRD and/or TEM. Nanoparticles made by the processes. Processes of use of the nanoparticles.
Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and/or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease. Further described herein is a method of evaluating a treatment for Lyme disease. The method includes comparing a glycosylation profile of the patient with glycosylation profiles associated with successful/unsuccessful treatments.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
72.
MULTI COLOR WHOLE-GENOME MAPPING AND SEQUENCING IN NANOCHANNEL FOR GENETIC ANALYSIS
In one aspect, the invention provides universal multi-color mapping strategy in nanochannels combining conventional sequence-motif labeling system with Cas9 mediated target-specific labeling of any 20-base sequences (20mers) to create custom labels and detect new features. The sequence-motifs are labeled with green fluorophores and the 20mers are labeled with red fluorophores. Using this strategy, it is not only possible to detect the (structural variants) SVs but it is also possible to utilize custom labels to interrogate the features not accessible to motif-labeling, locate breakpoints and precisely estimate copy numbers of genomic repeats. In another aspect, the invention provides CRISPR-Cas9 enabled whole-genome sequencing.
A two-dimensional particle including: one or plural layers, the one or plural layers having a layer body represented by: MmXn, wherein M is at least one metal of Group 3, 4, 5, 6, or 7, X is a carbon atom, a nitrogen atom, or a combination thereof, n is 1 to 4, m is more than n but not more than 5, and a modifier or terminal T existing on a surface of the layer body, wherein T is at least one selected from a hydroxyl group, an amine group, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, an oxygen atom, a sulfur atom, a selenium atom, a tellurium atom and a hydrogen atom; a metal cation is at least one cation selected from Na and K, and a content of Li in the two-dimensional particle is less than 0.002% by mass.
C01B 32/907 - OxycarbidesSulfocarbidesMixture of carbides
A61B 5/263 - Bioelectric electrodes therefor characterised by the electrode materials
B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
C08K 9/02 - Ingredients treated with inorganic substances
By combining two-dimensional (2D) transition metal oxide and/or carbo-oxides with sulfur, one can form cathodes for use in Li—S batteries, which batteries in turn exhibit high capacity and other attractive characteristics. Accordingly, provided herein are methods, comprising: forming an admixture that comprises sulfur, a 2D transition metal carbo-oxide, and optionally a conductive material. Also provided are electrodes, comprising sulfur, a 2D transition metal carbo-oxide, and optionally a conductive material. Further provided are energy cells, the energy cell comprising a first electrode according to the present disclosure. Additionally provided are methods, the methods comprising discharging an energy cell according to the present disclosure or charging an energy cell according to the present disclosure. Also provided are electrical devices, comprising an energy cell according to the present disclosure.
The disclosure provides a human-safe method of killing or controlling insects using a non-toxic composition comprising erythritol ((2R,3S)-butane-1,2,3,4-tetraol). The disclosure also provides non-toxic compositions comprising erythritol suitable for killing insects in residential, commercial, and agricultural locales.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
In absence of electrical approaches for realization of highly stable RF oscillator, opto-electronic oscillators (OEO) techniques are provided, where self-forced oscillation techniques using long optical delays demonstrate significant short-term and long-term frequency stability. Fully integrated opto-electronic oscillator chip (IOEC) may be the most efficient realization of an RF frequency synthesizer in terms of operation frequency (covering microwave and millimeter wave), size (<10 cm3), ruggedness to environmental effects of temperature (−40 to 80C), vibration (up to 40g), low timing jitter (<5fs for 40 GHz carrier), and wall-plug efficiency (output power >10 dBm from under 1 W power). A free-running III-V (primarily InP) based multi-mode laser (MML) diodes is designed with large mode number (e.g., over 60 modes) and intermodal oscillation frequency compatible with desired RF carrier signal (e.g., 1-40 GHz).
Government of USA, by The Secretary of the Army (USA)
Inventor
Palmese, Giuseppe R.
Kinaci, Emre
Lascala, John J.
Abstract
A polymerizable monomer prepared by reacting at least one epoxidized cardanol with (meth)acrylic anhydride or (meth)acryloyl chloride in the presence of one or more of triethylamine, tertiary amines, pyridines and pyridine derivatives; wherein the epoxidized cardanol is formed by epoxidation of an unsaturation site of a cardanol having the formula (I): wherein R is selected from hydrogen and an alkyl, or alkenyl group having 1-6 carbon atoms, and n is 7, 10, or 13, a polymer and resin made form the polymerizable monomer, and a method of preparing such a polymer. The resin created from this monomer is suitable for moderate temperature composites and coatings applications.
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C08F 222/20 - Esters containing oxygen in addition to the carboxy oxygen
78.
METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS
Methods and uses of using Sigma1 inhibitors are provide herein, including diagnostic methods for predicting or identifying quantitatively whether a human tumor is responsive or non-responsive to treatment with Sigma1 inhibition are also provided.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
79.
WEARABLE AND PORTABLE SMART ACTUATION DEVICE FOR DVT RISK MITIGATION: DEEP VEIN THROMBOSIS PREVENTION DEVICE (DVT-PD)
A deep vein thrombosis prevention device (DVT-PD) is a wearable device for the lower extremities senses the user's dynamic or static movements and actuates accordingly to lower DVT risks. The device uses a comprehensive control system together with an integrated machine learning model. to classify, manage, direct, and regulate signals and the behavior of the device.
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
80.
Dendrite-Free, Wide Temperature Range Lithium Metal Batteries Enabled by Hybrid Network Ionic Liquids
Ionic liquid N-methyl-N-propyl-pyrrolidinium bis(fluorosulfonyl)imide (Pyr13FSI) was introduced into a hybrid network to obtain a series of gel polymer electrolytes (GPEs). Mechanical and electrochemical properties of the GPEs were tuned through controlling the network structure and ionic liquid contents, and ionic conductivity higher than 1 mS cm−1 at room temperature was achieved. The newly developed GPEs are flame-retardant and show excellent thermal and electrochemical stability as well as ultra-stability with lithium metal anode. Symmetrical lithium cells with the GPEs exhibit a stable cycling over 6800 h at a current density of 0.1 mA cm−2 and stable lithium stripping-plating at 1 mA cm−2, the highest current density reported for ionic liquid-based GPEs. Moreover, Li/LiFePO4 batteries with the obtained GPEs exhibit desirable cycling stability and rate performance over a wide temperature range from 0° C. to 90° C.
A key-based interleaver for enhancement the security of wireless communication includes a physical layer communication channel key to provide security even when the software encryption key is compromised. A method of creating a secure communication link using a physical layer interleaving system includes implementing a key policy implementation that utilizes temporal dependency and interleaving bits using a flexible inter and intra-block data interleaver.
The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
83.
Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
84.
Use of cold atmospheric pressure plasma to treat warts
A method for treating a wart on skin of a patient includes guiding non-thermal, atmospheric pressure plasma over areas of the tissue having the wart for a length of time effective to give rise to an at least partial amelioration of the wart.
Methods of making a cathode active material, including steps of: a) mixing a conductive polymer, a nitrogen containing polymer or a combination of a conductive polymer and a nitrogen-containing polymer with sulfur in the presence of a solvent to form a mixture, using a weight ratio of the conductive polymer and/or nitrogen containing polymer to the sulfur of from about 1:2 to about 1:8; and b) heating the mixture to a temperature of from about 250#C to about 400#C under a pressure of from about 0.05 bar to about 2.0 bar to form the cathode active material. A cathode active material formed by the method and cells and batteries employing the cathode active material.
Described herein is method of treating and/or ameliorating a wound in a subject in need thereof. The method includes measuring an expression of a first and second panel of genes from a sample from the wound, wherein when at least one gene from the first panel is expressed, a pro-inflammatory agent is administed to the subject, and wherien when at least one gene from the second panel is expressed, an anti-inflammatory or M2 macrophage-promoting agent is administered to the subject, thus treating and/or ameliorating the wound in the subject.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
DREXEL UNIVERSITY (USA)
Inventor
Watson, Amanda
Kendell, Claire
Lee, Insup
Weimer, James
Abstract
Methods and devices for advanced spectroscopy are described herein. In one aspect, a method for determining levels of a biomarker of a user by a mobile device can include: generating a first light having a first wavelength; collecting emission signals resulting from the first light interacting with the user; measuring emission counts of the emission signals over a period of time; causing to be determined at least one of (i) a level of the biomarker of the user and (ii) a change in the levels of the biomarker of the user over the period of time based on the measured emission counts; and generating a notification indicative of the at least one of (i) a level of the biomarker of the user and (ii) a change in the levels of the biomarker of the user.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
88.
TUMOR BED IMPLANT FOR MULTIMODALITY TREATMENT OF AT RISK TISSUE SURROUNDING A RESECTION CAVITY
A device having a biocompatible polymer as a body and regularly spaced radiation seeds and regularly spaced magnetic materials disposed of within the body of the biocompatible polymer, or uniformly distributed liquid radiation and magnetic fluid materials within a polymer slab, hollow thick wall polymer shell, or thin wall polymer balloon, as suitable for surgical placement within a resection cavity for treatment of at-risk tissue in the tumor margin with local hyperthermia in combination with radiation and potentially also with chemotherapy and/or immunotherapy that is slowly released from the biocompatible polymer.
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
SINAI HEALTH SYSTEM (Canada)
DREXEL UNIVERSITY (USA)
THE WISTAR INSTITUTE (USA)
UNIVERSITY OF LEEDS (United Kingdom)
Inventor
Greenberg, Roger
Sicheri, Frank
Zeqiraj, Elton
Salvino, Joseph M.
Abstract
The present disclosure provides for techniques using BRISC deubiquitinating enzyme inhibitors of formula (I) for treating and/ or preventing systemic lupus erythematosus (SLE). Accordingly, the present disclosure provides for compositions and methods for treating or preventing a disease or disorder mediated by inhibition of type I interferon receptor (IFNAR1) signaling.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
An emergency C-Section task trainer includes a rigid frame, a simulated torso having an abdomen area mounted within the frame, and a simulated uterus in the torso below the abdomen area. A simulated fetus is located in the uterus. A plurality of first fluid conduits extends across the abdomen area and a plurality of second fluid conduits extends across the uterus.
A system develops classifiers that can aid medical professionals by diagnosing whether or not a patient has a medical condition like pneumothorax. The system breaks the task into multiple steps, using Y0L0v4 to extract relevant regions of the video and a 3D sparse coding model to represent video features. Given the difficulty in acquiring positive training videos, the inventors trained a small-data classifier with a maximum of 15 positive and 32 negative examples. To counteract this limitation, the inventors leveraged subject matter expert (SME) knowledge to limit the hypothesis space, thus reducing the cost of data collection. The inventors present results using two lung ultrasound datasets and demonstrate that the inventors' model is capable of achieving performance on par with SMEs in pneumothorax identification.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
92.
SYSTEM TO DEFEND AGAINST PUPPETEERING ATTACKS IN AI-BASED LOW BANDWIDTH VIDEO
A system defends against puppeteering attacks in low bandwidth talking head videoconferencing systems. The defensive system is a software that can be embedded within existing platforms or an operating system and it exploits the fact that the facial expression and pose information sent to the receiver inherently contain biometric information about the driving speaker. The system leverages this information to obtain measurements of the biometric distance between the driving and reconstructed speaker. If the biometric distance becomes large, this indicates that the driving speaker is a different person than the reconstructed speaker. The system then flags the video transmission as a puppeteering attack.
G06V 40/40 - Spoof detection, e.g. liveness detection
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
A dynamic capacitive power transfer system for an elevator that can realize the real-time powering of the elevator when it is in the moving status. It includes a metal track along the building side as the power transmitter and a piece of metal at the elevator side as the power receiver. There is a gap between the transmitter and receiver, and up to kW power can be transferred wirelessly and efficiently to serve the air conditioner, lightning, and other electronic devices in the moving car. The steel wheels and ropes may be used to connect the moving car to the earth ground, which contributes to form the current returning loop. It eliminates the electric cables and the corresponding flexible cable carrier system for the linear movement.
Described herein is a method of treating, ameliorating, and/or preventing post-operative pain in a subject using certain compositions recited in the disclosure. The method comprises administering to the subject a therapeutically effective of a composition comprising a small extracellular vesicle (sEV) or an exosome released by a macrophage. Also described herein is a method of performing surgical operation. The method comprises performing a surgery on the subject, as well as administering to the subject the composition comprising the sEV or exosome herein.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/04 - Centrally acting analgesics, e.g. opioids
The present application relates to a multifunctional-damage responsive biofiber and methods of forming thereof, comprising: a core comprising a polymeric fiber; a crosslinked endospore loaded hydrogel layer coating the core, wherein the hydrogel layer is formed with: a solution comprising endospores, one or more anionic polymers, and one or more crosslinking agents; and a (co)polymer shell encapsulating the hydrogel layer, wherein the shell has one or more layers which may be the same or different, and each of the one or more layers is formed with a (co)polymer selected from the group consisting of nitrocellulose (NITR), epoxy Resin (ER), polymethylmethacrylate (PMMA), polyvinylidene fluoride (PVDF), cyanoacrylate adhesive (CYA), polystyrene (PS), polylactic acid (PLA), and combinations thereof. This application also relates to methods for self-healing a matrix material including impregnating a matrix material with the multi-functional damage-responsive biofiber.
Provided are methods for etching MAX-phase materials to produce MXenes, the etching being accomplished by a salt, one or both of a polar and a non-polar solvent, and optionally a crown ether, the etching also being optionally performed in a water-free or essentially water-free manner. Also provided are related systems and methods.
B01J 4/00 - Feed devicesFeed or outlet control devices
B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
97.
COMPOSITIONS AND METHODS FOR TREATING A DISORDER OR DEFECT IN SOFT TISSUE
The present invention encompasses methods and compositions for generating a biomimetic proteoglycan. The invention includes methods of treating a disease, disorder, or condition of soft tissue using a biomimetic proteoglycan.
Backpropagation enabled neural network optimization, but is still expensive at scale. An efficient alternative for neural networks must reduce scaling costs and provide high-efficiency optimizations. The presented solution for feed-forward layers is extended compositionally, for transformers containing feed-forward and self-attention layers. These train complex models modularized by self-attentive feed-forward units (SAFFUs), defining efficient architectures that generalize over much less data. Results demonstrate outperformance of backpropagation (alone), compared to application of backpropagation after explicit solutions, which uncover better optima from less data. Ablations train a roadmap of 245 transformers to determine specifications for the SAFFU- transformer, showing several architectural variants appear quite performant. The most performant models appear to not be the most parameterized. Summarizing, well-generalized SAFFU models are efficiently reachable, their architectural explorability via explicit solutions is cheaper and more robust than by backpropagation, and their explicit solutions could be useful for low-resource hardware, where Al might be embodied.
Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and/or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
An integrated portable extremely fast charger (XFC) may be installed for heavy-duty off-road vehicles, such as tractors and combine harvesters. The XFC shortens the charging period of plug-in hybrid electric vehicles (PHEVs) and battery electric vehicles (BEVs) by providing >500 kW in a single charger. The proposed XFC integrates a solar farm and local energy storage system (ESS) such that the local grid only needs to provide the power gap between the vehicle battery and the local ESS during charging events, yielding a low-cost XFC installation and higher renewable energy penetration. Two design approaches for the XFC, conductive and wireless, are based on multiphase interleaved dc-dc converter circuit, permitting flexible access to electricity. Smart fault protection mechanism is also proposed to achieve high safety during charging events. The hexagonal prism charger may be integrated into the power electronic devices with a transformer, yielding a high compactness and power density.
